If we unraveled the DNA of the 46 chromosomes of a single human cell, it would barely measure 2 meters. If we did the same with the rest of the body, if we aligned the 3 billion base pairs of its 5 trillion cells, we could travel the distance from the Earth to the Sun more than 100 times. It seems unreachable. However, that is the unit of knowledge of the large sequencing projects achieved in 2023. From the generation of the human pangenome to cell-by-cell maps of the brain and kidneys, scientists this year have completed several omics collaborative projects stored in large international databases. Now, what’s the plan?

Fauna Bio Inc. has signed a multi-year agreement with Eli Lilly and Co. to apply Fauna’s Convergence artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.

Researchers have used explainable artificial intelligence (explainable AI) to find structurally new antibiotics with minimal toxicity. They reported their findings online in Nature on Dec. 20, 2023. In animal testing, compounds identified via the method showed that they had activity against drug-resistant gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious bacterial public health threats.

Postera Inc. has announced a multitarget collaboration with Amgen Inc. that seeks to leverage Postera’s artificial intelligence (AI) platform, Proton, an innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to five small-molecule programs.

Ibio Inc. has expanded its artificial intelligence (AI)-powered technology offering with the launch of Shieldtx, an antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue.

Can-Fite Biopharma Ltd. has entered into an agreement with Collaborations Pharmaceuticals Inc. (CPI) to develop anticancer drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques.

Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?

Biomap (Beijing) Intelligent Technology Co Ltd. has entered into a strategic collaboration with Sanofi SA to co-develop cutting-edge artificial intelligence (AI) modules for biotherapeutic drug discovery by leveraging Biomap’s AI platform.